Investors | Radiopharm Theranostics

annual reportS

September 2022

RAD Annual Report June 2022

September 2022

RAD ESG Report 2022

shareholder newsletter

May 2023

Radiopharm Newsletter 1st Quarter 2023

December 2022

Radiopharm Newsletter December 2022

July 2022

Radiopharm Newsletter July 2022

March 2022

Radiopharm Newsletter March 2022 - Meet our CEO in Australia

ANalyst coverage

June 2023

Diamond Equity Research Update 5 June 2023

June 2023

Bell Potter Research update Valuation at 25 cents per share 1 Jun 2023

April 2023

Jones Research - Initiation of Coverage Price Target 75 cents per share

March 2023

Bell Potter Initiation of Coverage - Going After Cancer

corporate governance

Radiopharm Theranostics Prospectus and Supplementary Disclaimers

Radiopharm Theranostics Prospectus

Radiopharm Theranostics Supplementary Prospectus

Corporate Governance

corporate policies

Privacy Policy

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.